Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke
Randomized study in people · 2014
- What was studied
- ESCORT; 272 acute ischemic-stroke patients
- Main finding
- Double-blind placebo-controlled comparison of repeated Cortexin, one course followed by placebo, and placebo. Authors reported functional and pharmacoeconomic benefits.
Reported findings and study design
272 acute-stroke patients in a multicenter double-blind placebo comparison. Three treatment sequences; Cortexin 10 mg IM three times daily, with one or two ten-day courses; 70-day observation and four visits.
Population or model ESCORT; 272 acute ischemic-stroke patients
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Best reported treatment sequence | Two Cortexin courses | Exact scale scores and arm-level results absent from abstract |
This is the 272-participant Cortexin trial included in later reviews, not another independent trial population.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Read alongside the independent 2023 Cochrane assessment; favorable scales do not establish mortality benefit.
- The related ESCORT publications describe one trial.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Aliferova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MIu, Meshkova KS, Salimov KA, Stakhovskaia LV, Chefranova ZhIu, Shamalov NA. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke Zh Nevrol Psikhiatr Im S S Korsakova 114(4):41-46. PMID 24874316